VPA-985 IN PATIENTS WITH HYPONATREMIA

VPA-985 用于低钠血症患者

• 批准号: 6276556
• 负责人: MARC THIBONNIER
• 金额: $ 1.83万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276556
• 关键词: blood pressure; blood volume; cell proliferation; clinical research; clinical trial phase I; congestive heart failure; diuresis; drug screening /evaluation; homeostasis; human subject; human therapy evaluation; hyponatremia; liver cirrhosis; nephrotic syndrome; osmotic pressure; pharmacokinetics; second messengers; secretin; secretion; vasopressins

Vasopressin (AVP) is a peptide hormone actively involved in the regulatin of body fluid osmolality, blood volume, blood pressure, and cell prliferation via the stimulation of specific membrane-bound receptors classified into pituitary subtypes having distinct pharmacological profiles and intracellular second messengers. The secretion of AVP is an absolute requirement for the maintenacne of fluid homeostasis. An agent that increases urine output by producing a free water diuresis would be a significant advantage in conditions such as hyponatremia of congestive heart failure, liver chirrhosis, nephrotic syndrome and the syndrome of inappropriate secretin of antidiuretic hormone (SIADH). This study is designed to evaluate the effecacy, safety, and tolerance of VPA-985, a selective non-peptidic orally active AVP antagonist, in patients with hyponatremia due to drug induced SIADH. Preliminary pharmacokinetic and pharmacodynamic parameters will be asessed.

加压素（AVP）是一种积极参与的肽激素 体液渗透压，血容量，血压和血压的调节素 通过刺激特定膜结合的细胞体积 分类为具有不同的垂体亚型的受体 药理学轮廓和细胞内第二使者。 这 AVP的分泌是液体维护的绝对要求 稳态。 通过产生免费的代理来增加尿量 在诸如 充血性心力衰竭的低钠血症，肝硬化，肾病 综合征和抗利尿剂不适当的综合征 激素（SIADH）。这项研究旨在评估效率， VPA-985的安全性和耐受性，一种选择性的非肽口服活性 AVP拮抗剂，因药物诱导的低钠血症患者 siadh。 初步的药代动力学和药效学参数将 陷入困境。